#### This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/26/2024 10:41 AM

# **BUY** UltraTech Cement

# In-line quarter; firmly affirms capacity guidance

# **Cement** > Result Update > **January 19, 2024**

UltraTech Cement reported broadly in-line operational performance in Q3FY24 with consolidated EBITDA increasing 39% YoY/28% QoQ to Rs32.5bn. Blended EBITDA/t improved by Rs236/t (QoQ) to Rs1,191 mainly driven by increased average realization (+2% QoQ). Volume trajectory tapered down to 6% YoY (2% QoQ) to 27.3mt (9MFY24: +14% YoY). The company has increased its growth capex guidance to Rs90bn each in FY24-FY25 vs. earlier guidance of Rs60-70bn p.a. UltraTech has reiterated to reach ~180mt domestic grey cement capacity by FY27E (~10% CAGR, excluding Kesoram Industries), which would enable it to post industry-leading volume growth over the next few years. We have yet to factor in Kesoram's acquisitions in our estimates. Factoring in little lower volume growth, we have cut our FY25-26E EBITDA estimates by 1-4% and revised down TP to Rs11,200/sh, based on 18x Dec25 EV/E. Maintain BUY.

UltraTech Cement: I	Financial Sr	apshot (Co	onsolidated	)	
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	5,25,988	6,32,400	6,95,853	7,62,053	8,53,622
EBITDA	1,15,143	1,06,198	1,27,861	1,53,828	1,78,755
Adj. PAT	56,665	50,639	68,635	85,676	1,04,606
Adj. EPS (Rs)	248.9	175.4	237.7	296.8	362.3
EBITDA margin (%)	21.9	16.8	18.4	20.2	20.9
EBITDA growth (%)	(0.5)	(7.8)	20.4	20.3	16.2
Adj. EPS growth (%)	35.0	(29.5)	35.5	24.8	22.1
RoE (%)	12.0	9.7	12.0	13.5	14.8
RoIC (%)	10.8	9.3	11.7	13.0	14.2
P/E (x)	51.4	57.5	42.5	34.0	27.9
EV/EBITDA (x)	25.6	27.7	23.1	19.2	16.4
P/B (x)	5.8	5.4	4.9	4.4	3.9
FCFF yield (%)	1.4	0.9	0.3	0.7	1.4

Source: Company, Emkay Research

### **Result Summary**

UltraTech's India operations EBITDA increased by 40% YoY/29% QoQ at Rs31.5bn with EBITDA/t at Rs1,208. Capacity utilization improved marginally by 200bps QoQ to 77% (Q3FY23: 83%) and management is targeting it to improve to 80-85% utilization in Q4FY24. Industry demand during the quarter was lackluster (3-4% YoY) owing to elections in four major states, unseasonal rainfall in the South, construction ban in NCR, and sand shortage in some of the areas. Grey cement realization increased 2.1% YoY/ 2.8% QoQ to Rs5,499. Total cost/t declined 3% YoY/2% QoQ to Rs4,936 mainly led by a decline in RM+P&F cost (Rs76/t). Growth capex guidance has been revised to Rs90bn p.a. each in FY24/FY25 vs. earlier guidance of Rs65-70bn p.a. Net debt increased by Rs6.2bn QoQ to Rs55bn as on Dec-23.

What we liked: Increased capex intensity.

What we did not like: Increased net debt and higher operating overheads.

### Earnings call KTAs:

i) On the demand front, the company has started witnessing gradual improvement and is expecting 80-85% capacity utilization in Q4FY24; ii) Spot cement prices are marginally lower than average cement prices in Q3FY24; iii) Blended fuel cost per kcal stood at Rs2.04 in Q3FY24 vs. Rs2.18 in Q2FY24. Fuel consumption cost stood at \$150/t in Q3FY24 vs. \$162/t in Q2FY24. Management is expecting at least 7-8% reduction in fuel cost over the next two quarters; iv) It has a total growth capex outline of Rs250bn, of which Rs180bn will be likely to be spent in FY24-25. There will be an additional maintenance capex of Rs10-12bn p.a.; v) Management indicated that all expansions are clinker-backed and will likely add 14mt/10-12mt under phase II/III expansions. Projects in states like Rajasthan, Bihar, and U.P. will be eligible for incentives; vi) Effective date of the merger of Kesoram's acquisition is likely to be from 1-Apr-24.



### TARGET PRICE (Rs): 11,200

Target Price – 12M	Dec-24
Change in TP (%)	(1.8)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	11.0
CMP (19-Jan-24) (Rs)	10,093.7
Stock Data	Ticker
52-week High (Rs)	10,526
52-week Low (Rs)	6,604
Shares outstanding (mn)	288.7
Market-cap (Rs bn)	2,914
Market-cap (USD mn)	35,079
Net-debt, FY24E (Rs mn)	39,217
ADTV-3M (mn shares)	
ADTV-3M (Rs mn)	3,326.8
ADTV-3M (USD mn)	40.0
Free float (%)	-

# Nifty-50 INR/USD Shareholding, Dec-23 Promoters (%)

FPIs/MFs (%)

21,622

83.1

60.0

18.2/14.3

Price Performa	ance		
(%)	1M	3M	12M
Absolute	0.8	18.5	40.0
Rel. to Nifty	-	7.5	17.2

#### 1-Year share price trend (Rs)



#### **Dharmesh Shah**

dharmesh.shah@emkayglobal.com +91 22 6612 1255

Cheragh Sidhwa

cheragh.sidhwa@emkayglobal.com +91 22 6612 1219

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **Quarterly Analysis**

# Exhibit 1: Actual vs. Estimates (Q3FY24)

(Rs mn)	Actual	Estima	ites	Variatio	on (%)	Comment
	Actual	Emkay	Consensus	Emkay	Consensus	
Net sales	164,870	164,319	170,290	0.3	(3.2)	
EBITDA	32,546	31,679	33,095	2.7	(1.7)	In-line
PAT	17,770	16,985	18,202	4.6	(2.4)	
Volumes (mt)	27.3	27.3		-		
Cement realization (Rs/ton)	6,035	6,015		0.3		
EBITDA (Rs/ton)	1,191	1,160		2.7		

Source: Bloomberg, Emkay Research

Exhibit 2: India Operations -	- Quarterly									
India operations (Rs mn)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	YoY (%)
Net Sales	147,550	178,850	170,070	151,950	158,820	7.6	4.5	424,740	480,840	13.2
Other Operating Income	2,340	2,270	2,180	2,810	2,520	7.7	(10.3)	6,510	7,510	15.4
Revenue	149,890	181,120	172,250	154,760	161,340	7.6	4.3	431,250	488,350	13.2
Expenditure	127,450	148,810	142,250	130,280	129,860	1.9	(0.3)	360,700	402,390	11.6
Total RM	21,290	30,240	27,680	23,540	24,510	15.1	4.1	62,380	75,730	21.4
Power and Fuel	46,550	51,080	47,300	42,070	40,030	(14.0)	(4.8)	126,180	129,400	2.6
Freight	34,440	41,580	40,690	34,780	35,810	4.0	3.0	97,270	111,280	14.4
Staff Cost	6,640	6,880	6,760	7,780	7,370	11.0	(5.3)	19,330	21,910	13.3
Other Expenditure	18,530	19,030	19,820	22,110	22,140	19.5	0.1	55,540	64,070	15.4
EBITDA	22,440	32,310	30,000	24,480	31,480	40.3	28.6	70,550	85,960	21.8
Depreciation	6,940	7,330	7,200	7,680	7,540	8.6	(1.8)	20,400	22,420	9.9
EBIT	15,500	24,980	22,800	16,800	23,940	54.5	42.5	50,150	63,540	26.7
Other Income	950	1,510	2,090	1,580	1,400	47.4	(11.4)	3,530	5,070	43.6
Interest	1,940	1,750	1,920	2,110	2,370	22.2	12.3	5,810	6,400	10.2
РВТ	14,510	24,740	22,970	16,270	22,970	58.3	41.2	47,870	62,210	30.0
Total Tax	4,620	8,220	5,880	4,150	5,860	26.8	41.2	15,090	15,890	5.3
Adjusted PAT	9,890	16,520	17,090	12,120	17,110	73.0	41.2	32,780	46,320	41.3
Adjusted EPS (Rs)	34.3	57.2	59.2	42.0	59.3	73.0	41.2	113.6	160.5	41.3

Source: Company, Emkay Research

# Exhibit 3: India operations – Quarterly analysis on a per-ton basis

(Rs/ton)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	YoY (%)
Volumes (mt)	24.7	30.5	29.0	25.7	26.1	5.7	1.6	71	81	13.9
Blended Realization	5,983	5,866	5,862	5,922	6,094	1.9	2.9	6,083	6,049	(0.6)
Raw-material Cost	863	992	954	917	941	8.9	2.5	880	938	6.6
Power and Fuel Cost	1,888	1,675	1,630	1,640	1,536	(18.6)	(6.3)	1,780	1,603	(9.9)
Freight Cost	1,397	1,364	1,403	1,355	1,374	(1.6)	1.4	1,372	1,378	0.5
Staff Cost	269	226	233	303	283	5.0	(6.7)	273	271	(0.5)
Other Expenditure	751	624	683	862	850	13.1	(1.4)	783	794	1.3
Operating Cost	5,168	4,881	4,903	5,077	4,983	(3.6)	(1.9)	5,088	4,984	(2.0)
Other Operating Income	95	74	75	110	97	1.9	(11.7)	92	93	1.3
EBITDA	910	1,060	1,034	954	1,208	32.7	26.6	995	1,065	7.0

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 4: Consolidated financials (Quarterly)

							/ - / >			
(Rs mn)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (%)		9MFY23	9MFY24	YoY (%)
Net Sales	152,990	184,360	175,190	157,350	164,870	7.8	4.8	439,020	497,410	13.3
Other Operating Income	2,219	2,264	2,181	2,771	2,530	14.0	(8.7)	6,756	7,482	10.7
Revenue	155,209	186,624	177,371	160,121	167,400	7.9	4.5	445,776	504,892	13.3
Expenditure	131,851	153,399	146,879	134,612	134,854	2.3	0.2	372,802	416,346	11.7
Total RM	22,437	31,711	29,440	24,942	26,554	18.4	6.5	65,439	80,936	23.7
Power and Fuel	48,731	53,089	48,812	43,853	41,780	(14.3)	(4.7)	131,824	134,445	2.0
Freight	34,794	41,954	41,008	35,118	36,209	4.1	3.1	98,137	112,335	14.5
Staff Cost	6,942	7,164	7,070	8,123	7,689	10.8	(5.3)	20,225	22,882	13.1
Other Expenditure	18,947	19,480	20,550	22,577	22,622	19.4	0.2	57,177	65,749	15.0
EBITDA	23,359	33,225	30,492	25,509	32,546	39.3	27.6	72,974	88,546	21.3
Depreciation	7,232	7,617	7,491	7,978	7,835	8.3	(1.8)	21,263	23,304	9.6
EBIT	16,126	25,608	23,001	17,531	24,711	53.2	41.0	51,710	65,243	26.2
Other Income	1,266	1,215	1,737	1,671	1,405	11.0	(15.9)	3,816	4,813	26.1
Interest	2,153	1,914	2,108	2,339	2,622	21.8	12.1	6,313	7,069	12.0
РВТ	15,240	24,909	22,631	16,863	23,494	54.2	39.3	49,213	62,988	28.0
Total Tax	4,647	8,223	5,766	4,094	5,804	24.9	41.8	15,206	15,663	3.0
Adjusted PAT	10,593	16,686	16,865	12,769	17,690	67.0	38.5	34,007	47,324	39.2
(Profit)/loss from JVs/Ass/MI	(11)	(27)	17	46	80	(823.6)	74.6	(27)	142	(623.5)
PAT after MI	10,582	16,660	16,882	12,815	17,770	67.9	38.7	33,980	47,467	39.7
Extraordinary Items	-	-	-	-	-					
Reported PAT	10,582	16,660	16,882	12,815	17,770	67.9	38.7	33,980	47,467	39.7
Adjusted EPS (Rs)	36.7	57.7	58.5	44.4	61.6	67.9	38.7	117.7	164.5	39.7
(%)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (bps)	QoQ (bps)	9MFY23	9MFY24	YoY (bps)
EBITDAM	15.0	17.8	17.2	15.9	19.4	439	351	16.4	17.5	117
EBITM	10.4	13.7	13.0	10.9	14.8	437	381	11.6	12.9	132
EBTM	9.8	13.3	12.8	10.5	14.0	422	350	11.0	12.5	144
PATM	6.8	8.9	9.5	8.0	10.6	374	259	7.6	9.4	174
Effective Tax Rate	30.5	33.0	25.5	24.3	24.7			30.9	24.9	

Source: Company, Emkay Research

### Exhibit 5: Consolidated quarterly analysis on a per-ton basis

(Rs/ton)	3QFY23	4QFY23	1QFY24	2QFY24	30FY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	YoY (%)
Volumes (mt)	25.9	31.7	30.0	26.7	27.3	5.7	2.4	74.0	84.0	13.5
. ,					-					
Blended Realization	5,918	5,809	5,847	5,895	6,035	2.0	2.4	5,934	5,924	(0.2)
Raw Material Cost	868	999	983	935	972	12.0	4.0	884	964	9.0
Power and Fuel Cost	1,885	1,673	1,629	1,643	1,529	(18.9)	(6.9)	1,782	1,601	(10.1)
Freight Cost	1,346	1,322	1,369	1,316	1,325	(1.5)	0.7	1,326	1,338	0.9
Staff Cost	269	226	236	304	281	4.8	(7.5)	273	272	(0.3)
Other Expenditure	733	614	686	846	828	13.0	(2.1)	773	783	1.3
Operating Cost	5,101	4,833	4,903	5,044	4,936	(3.2)	(2.1)	5,039	4,958	(1.6)
Other Operating Income	86	71	73	104	93	7.9	(10.8)	91	89	(2.4)
EBITDA	904	1,047	1,018	956	1,191	31.8	24.6	986	1,055	6.9

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 6: We change our EBITDA estimates by 1-4% for FY25-26E

	I	FY24E			FY25E		FY26E			
(Rs mn)	Old	New	Chg. (%)	Old	New	Chg. (%)	Old	New	Chg. (%)	
Revenue	721,662	695,853	(3.6)	789,379	762,053	(3.5)	876,901	853,622	(2.7)	
EBITDA	141,902	127,861	(9.9)	159,896	153,828	(3.8)	180,603	178,755	(1.0)	
PAT	80,060	68,851	(14.0)	94,146	85,622	(9.1)	110,742	104,547	(5.6)	

Source: Emkay Research

# Exhibit 7: We maintain BUY with a TP of Rs11,200/share, based on Dec-25E EV/E of 18x

EV/E valuation	
Dec-25E EBITDA (Rs bn)	173
EV/E (x)	18
Enterprise Value (Rs bn)	3,154
Net debt (Dec-24E; Rs bn)	41
Equity value (Rs bn)	3,113
No. of shares (mn)	289
Dec-24E Target Price (Rs/share)	11,200*

Source: Emkay Research. \*Our TP also includes Kesoram's value of Rs415

# Exhibit 8: Annual Financials

Kan Aaamatiana	5710	EV10	EV 20	EV21	FV22	EV22	EV24E	EVALE	EVACE		CAGR (%)
Key Assumptions	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY18-23	FY23-26E
Capacity (mt)	86	100	115	118	121	138	142	160	169	10.0	7.1
Volumes (mt)	65	76	82	86	94	106	116	125	138	10.4	9.2
Utilization (%)	82	82	77	74	78	82	82	78	81		
Blended Realization (Rs/ton)	4,795	4,815	5,038	5,118	5,502	5,895	5,899	6,008	6,121	4.2	1.3
EBITDA/ton (Rs)	951	889	1,144	1,338	1,225	1,004	1,100	1,230	1,300	1.1	9.0
P&L (Rs bn)											
Revenue	314	374	421	447	526	632	696	762	854	15.0	10.5
EBITDA	61	68	94	116	115	106	128	154	179	11.6	19.0
Adj. Net Profit	25	24	38	56	57	51	69	86	105	15.5	27.4
Balance Sheet (Rs bn)											
Equity	264	284	391	442	504	544	598	667	751		
Net Debt	141	196	169	67	39	27	39	41	24		
Net Debt:EBITDA	2.3	2.9	1.8	0.6	0.3	0.3	0.3	0.3	0.1		
Net Debt:Equity	0.5	0.7	0.4	0.2	0.1	0.0	0.1	0.1	0.0		
Cash Flow (Rs bn)											
OCF before NWC change	40	47	65	87	93	74	96	113	136		
Change in NWC	(8)	(9)	5	23	(5)	(3)	(2)	(2)	(2)		
Capex	(180)	(15)	(17)	(18)	(56)	(61)	(95)	(101)	(101)		
FCF	(149)	23	53	91	32	10	(1)	10	33		
Return ratios (%)											
RoE	9.7	8.9	11.4	13.4	12.0	9.7	12.0	13.5	14.8		
RoCE	7.6	6.8	8.6	11.6	10.4	8.9	11.0	12.3	13.6	-	
RoIC	9.1	7.4	9.3	11.0	10.8	9.3	11.7	13.0	14.2		
Valuations (x)											
PER (x)						57.5	42.5	34.0	27.9		
EV/EBITDA (x)						27.8	23.0	19.2	16.5		
EV/ton (USD)						260	254	225	211		

Source: Company, Emkay Research

This report is intended for team emkay @whitemarquesolutions com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


# Exhibit 9: Annual analysis on a per-ton basis

(Rs/ton)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Blended Realization	4,795	4,815	5,038	5,118	5,502	5,895	5,899	6,008	6,121
YoY (%)	2.0	0.4	4.6	1.6	7.5	7.1	0.1	1.8	1.9
Raw-Material Cost	813	855	767	820	847	919	953	969	988
Power and Fuel Cost	981	1,103	1,029	964	1,291	1,749	1,577	1,527	1,545
Freight Cost	1,132	1,158	1,181	1,162	1,246	1,325	1,325	1,346	1,366
Staff Cost	280	270	305	272	270	259	264	263	256
Other expenses	706	619	691	618	717	725	767	761	752
YoY (%)	(5.6)	(12.3)	11.6	(10.6)	15.9	1.2	5.9	(0.9)	(1.1)
Total Operating Cost	3,911	4,005	3,973	3,836	4,371	4,976	4,886	4,865	4,907
Other Operating Income	68	79	79	56	95	85	87	88	86
Blended EBITDA	951	889	1,144	1,338	1,225	1,004	1,100	1,230	1,300
YoY (%)	(2.6)	(6.6)	28.7	17.0	(8.5)	(18.0)	9.5	11.9	5.6

Source: Company, Emkay Research



Exhibit 11: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

Source: Bloomberg, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **UltraTech Cement: Consolidated Financials and Valuations**

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	5,25,988	6,32,400	6,95,853	7,62,053	8,53,622
Revenue growth (%)	17.6	20.2	10.0	9.5	12.0
EBITDA	1,15,143	1,06,198	1,27,861	1,53,828	1,78,755
EBITDA growth (%)	(0.5)	(7.8)	20.4	20.3	16.2
Depreciation & Amortization	27,148	28,880	31,119	34,016	35,159
EBIT	87,996	77,318	96,742	1,19,812	1,43,596
EBIT growth (%)	(0.8)	(12.1)	25.1	23.8	19.9
Other operating income	8,908	9,020	10,129	10,940	11,815
Other income	5,078	5,031	6,225	7,109	8,259
Financial expense	9,447	8,227	11,375	12,155	11,741
РВТ	83,627	74,122	91,591	1,14,766	1,40,115
Extraordinary items	15,179	0	0	0	0
Taxes	27,079	23,429	23,173	29,036	35,449
Minority interest	(118)	54	(216)	54	60
Income from JV/Associates	0	0	0	0	0
Reported PAT	71,844	50,639	68,635	85,676	1,04,606
PAT growth (%)	35.0	(29.5)	35.5	24.8	22.1
Adjusted PAT	56,665	50,639	68,635	85,676	1,04,606
Diluted EPS (Rs)	248.9	175.4	237.7	296.8	362.3
Diluted EPS growth (%)	35.0	(29.5)	35.5	24.8	22.1
DPS (Rs)	38.0	47.5	59.4	72.5	0.0
Dividend payout (%)	15.3	27.1	25.0	24.4	0.0
EBITDA margin (%)	21.9	16.8	18.4	20.2	20.9
EBIT margin (%)	16.7	12.2	13.9	15.7	16.8
Effective tax rate (%)	32.4	31.6	25.3	25.3	25.3
NOPLAT (pre-IndAS)	59,502	52,880	72,266	89,500	1,07,266
Shares outstanding (mn)	288.7	288.7	288.7	288.7	288.7

Balance Sheet					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	2,887	2,887	2,887	2,887	2,887
Reserves & Surplus	5,01,467	5,40,359	5,95,266	6,63,807	7,47,492
Net worth	5,04,353	5,43,245	5,98,153	6,66,694	7,50,379
Minority interests	(31)	556	340	394	454
Deferred tax liability (net)	60,169	62,536	60,516	60,577	60,637
Total debt	1,02,028	99,008	1,11,008	1,31,008	1,31,008
Total liabilities & equity	6,66,520	7,05,345	7,70,017	8,58,673	9,42,478
Net tangible fixed assets	4,25,922	4,36,434	5,15,306	5,71,095	6,41,878
Net intangible assets	1,17,168	1,17,168	1,17,168	1,17,168	1,17,168
Net ROU assets	11,786	11,786	11,786	11,786	11,786
Capital WIP	47,773	40,349	26,398	38,192	34,373
Goodwill	62,502	63,293	63,293	63,293	63,293
Investments [JV/Associates]	3,931	12,478	12,478	12,478	12,478
Cash & equivalents	63,019	71,988	71,791	89,755	1,06,591
Current assets (ex-cash)	1,37,565	1,60,310	1,77,750	1,95,736	2,23,220
Current Liab. & Prov.	1,71,595	2,08,459	2,25,951	2,40,829	2,68,309
NWC (ex-cash)	(34,031)	(48,149)	(48,202)	(45,093)	(45,089)
Total assets	6,66,520	7,05,345	7,70,017	8,58,673	9,42,478
Net debt	39,010	27,020	39,217	41,253	24,416
Capital employed	6,66,520	7,05,345	7,70,017	8,58,673	9,42,478
Invested capital	5,51,798	5,80,531	6,59,351	7,18,249	7,89,036
BVPS (Rs)	1,747.2	1,881.8	2,072.0	2,309.4	2,599.3
Net Debt/Equity (x)	0.1	0.0	0.1	0.1	0.0
Net Debt/EBITDA (x)	0.3	0.3	0.3	0.3	0.1
Interest coverage (x)	0.1	0.1	0.1	0.1	0.1
RoCE (%)	13.6	12.0	14.0	15.6	16.9

Source: Company, Emkay Research

Cash Flows					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	83,627	74,122	91,591	1,14,766	1,40,115
Others (non-cash items)	(212)	2,721	0	0	0
Taxes paid	(27,079)	(23,429)	(23,173)	(29,036)	(35,449)
Change in NWC	(8,984)	14,119	52	(3,109)	(4)
Operating cash flow	94,165	99,555	1,03,950	1,20,591	1,42,174
Capital expenditure	(52,356)	(72,855)	(95,034)	(1,00,561)	(1,01,054)
Acquisition of business	58,054	(1,065)	(5,000)	(5,000)	(5,000)
Interest & dividend income	5,078	5,031	6,225	7,109	8,259
Investing cash flow	10,777	(68,889)	(93,809)	(98,451)	(97,795)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(1,02,699)	(3,021)	12,000	20,000	0
Payment of lease liabilities	(2,227)	0	0	0	0
Interest paid	(9,447)	(8,227)	(11,375)	(12,155)	(11,741)
Dividend paid (incl tax)	(10,970)	(10,970)	(13,727)	(17,135)	(20,921)
Others	1,689	(545)	(2,236)	115	120
Financing cash flow	(1,21,425)	(22,762)	(15,338)	(9,176)	(32,542)
Net chg in Cash	(16,484)	7,904	(5,197)	12,964	11,837
OCF	94,165	99,555	1,03,950	1,20,591	1,42,174
Adj. OCF (w/o NWC chg.)	1,03,149	85,436	1,03,897	1,23,700	1,42,177
FCFF	41,809	26,700	8,916	20,031	41,119
FCFE	(60,889)	23,680	20,916	40,031	41,119
OCF/EBITDA (%)	81.8	93.7	81.3	78.4	79.5
FCFE/PAT (%)	(107.5)	46.8	30.5	46.7	39.3
FCFF/NOPLAT (%)	70.3	50.5	12.3	22.4	38.3

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and Key R	atios				
Y/E March	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	51.4	57.5	42.5	34.0	27.9
P/CE(x)	34.8	36.6	29.2	24.3	20.8
P/B (x)	5.8	5.4	4.9	4.4	3.9
EV/Sales (x)	5.7	4.7	4.3	3.9	3.5
EV/EBITDA (x)	25.6	27.7	23.1	19.2	16.4
EV/EBIT(x)	33.9	38.2	30.5	24.7	20.5
EV/IC (x)	5.4	5.1	4.5	4.1	3.7
FCFF yield (%)	1.4	0.9	0.3	0.7	1.4
FCFE yield (%)	(2.0)	0.8	0.7	1.4	1.4
Dividend yield (%)	0.4	0.5	0.6	0.7	0.0
DuPont-RoE split					
Net profit margin (%)	10.8	8.0	9.9	11.2	12.3
Total asset turnover (x)	0.8	0.9	0.9	0.9	0.9
Assets/Equity (x)	1.5	1.3	1.3	1.3	1.3
RoE (%)	12.0	9.7	12.0	13.5	14.8
DuPont-RoIC					
NOPLAT margin (%)	11.3	8.4	10.4	11.7	12.6
IC turnover (x)	1.0	1.1	1.1	1.1	1.1
RoIC (%)	10.8	9.3	11.7	13.0	14.2
Operating metrics					
Core NWC days	(23.6)	(27.8)	(25.3)	(21.6)	(19.3)
Total NWC days	(23.6)	(27.8)	(25.3)	(21.6)	(19.3)
Fixed asset turnover	0.7	0.8	0.8	0.8	0.8
Opex-to-revenue (%)	63.0	67.8	65.7	63.9	63.1

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
05-Jan-24	10,016	11,400	Buy	Dharmesh Shah
30-Nov-23	9,004	9,550	Add	Dharmesh Shah
30-Nov-23	9,004	9,550	Buy	Dharmesh Shah
30-Nov-23	9,004	9,550	Buy	Dharmesh Shah
29-Oct-23	8,210	9,550	Buy	Dharmesh Shah
19-Oct-23	8,519	9,550	Buy	Dharmesh Shah
28-Sep-23	8,154	9,250	Buy	Dharmesh Shah
18-Sep-23	8,628	9,250	Buy	Dharmesh Shah
22-Jul-23	8,119	9,250	Buy	Dharmesh Shah
03-Jun-23	7,851	8,500	Buy	Dharmesh Shah
04-May-23	7,502	8,500	Buy	Dharmesh Shah
29-Apr-23	7,556	8,500	Buy	Dharmesh Shah
07-Apr-23	7,702	7,350	Buy	Dharmesh Shah
02-Mar-23	7,289	7,350	Buy	Dharmesh Shah
05-Feb-23	7,189	7,350	Buy	Dharmesh Shah
23-Jan-23	6,850	7,350	Buy	Dharmesh Shah
29-Dec-22	6,982	7,100	Buy	Dharmesh Shah
05-Dec-22	7,199	7,100	Buy	Dharmesh Shah
05-Nov-22	6,893	7,100	Buy	Dharmesh Shah
19-Oct-22	6,398	7,100	Buy	Dharmesh Shah
04-Oct-22	6,308	7,100	Buy	Dharmesh Shah
04-Sep-22	6,578	7,100	Buy	Dharmesh Shah
24-Jul-22	6,459	7,100	Buy	Dharmesh Shah
04-Jul-22	5,709	6,650	Buy	Dharmesh Shah
28-Jun-22	5,573	6,650	Buy	Dharmesh Shah
02-Jun-22	6,008	7,300	Buy	Dharmesh Shah
01-May-22	6,630	7,300	Buy	Dharmesh Shah
16-Mar-22	6,306	7,230	Buy	Dharmesh Shah
18-Jan-22	7,556	8,750	Buy	Dharmesh Shah
31-Dec-21	7,591	8,500	Buy	Dharmesh Shah
02-Dec-21	7,323	8,500	Buy	Dharmesh Shah
19-Oct-21	7,170	8,500	Buy	Dharmesh Shah
05-Sep-21	7,930	8,500	Buy	Dharmesh Shah
06-Aug-21	7,528	8,500	Buy	Dharmesh Shah
23-Jul-21	7,490	8,500	Buy	Dharmesh Shah
06-Jun-21	6,664	7,050	Buy	Dharmesh Shah
10-May-21	6,403	7,050	Buy	Dharmesh Shah
09-May-21	6,482	7,050	Buy	Dharmesh Shah
28-Apr-21	6,361	7,050	Buy	Dharmesh Shah

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup>An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of January 19, 2024
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of January 19, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the January 19, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 01/26/2024 10:41 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### OTHER DISCLAIMERS AND DISCLOSURES:

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.